Xinwei Han

Cancer immunotherapy beyond immune checkpoint inhibitors

A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy

Universal CARs, universal T cells, and universal CAR T cells

Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases

Molecular and histological correlations in liver cancer

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

Macrophages in immunoregulation and therapeutics

Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma

Hepatocellular carcinoma

Genetically engineered T cells for cancer immunotherapy

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

CD44 as a tumor biomarker and therapeutic target

Unraveling the Complex Interplay Between T Cell Metabolism and Function

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update

Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering

DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Chimeric antigen receptor T cells: a novel therapy for solid tumors

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment